<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paroxysmal hemicrania: Clinical features and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paroxysmal hemicrania: Clinical features and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Paroxysmal hemicrania: Clinical features and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Manjit S Matharu, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna S Cohen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features [<a href="#rid1">1,2</a>]. The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, and hemicrania continua [<a href="#rid3">3</a>].</p><p>This topic will review the epidemiology, clinical features, and diagnosis of paroxysmal hemicrania. Management and prognosis are reviewed separately. (See  <a class="medical medical_review" href="/d/html/3335.html" rel="external">"Paroxysmal hemicrania: Treatment and prognosis"</a>.)</p><p>Other trigeminal autonomic cephalalgias are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3326.html" rel="external">"Cluster headache: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3351.html" rel="external">"Cluster headache: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3336.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3338.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3342.html" rel="external">"Hemicrania continua"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">HISTORICAL ASPECTS</span><span class="headingEndMark"> — </span>Paroxysmal hemicrania was first described in 1974 [<a href="#rid4">4</a>]. The initial cases were characterized by daily headaches for years without remission, and the condition was termed "chronic paroxysmal hemicrania" [<a href="#rid5">5</a>]. Subsequently, it became apparent that not all patients experienced a chronic, unremitting course; in some patients, discrete headache bouts were separated by prolonged pain-free remissions [<a href="#rid1">1,6-11</a>]. This remitting pattern was named episodic paroxysmal hemicrania.</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Paroxysmal hemicrania is a rare condition. The exact incidence and prevalence of paroxysmal hemicrania are not known, but it has been reported in various parts of the world [<a href="#rid12">12-14</a>] and affects different races [<a href="#rid15">15,16</a>].</p><p>By one estimate, the prevalence of paroxysmal hemicrania is 1 to 3 percent of the prevalence of cluster headache [<a href="#rid17">17</a>]. Given that the prevalence of cluster headache is approximately 1 per 500 [<a href="#rid18">18</a>], the prevalence of paroxysmal hemicrania would be approximately 1 per 25,000. However, epidemiologic data are scarce and many cases of paroxysmal hemicrania are probably still overlooked.</p><p>In a headache epidemiology study of 1838 adults from Norway, no definite cases of paroxysmal hemicrania were confirmed, although a possible variant of chronic paroxysmal hemicrania was identified in one individual (0.05 percent) [<a href="#rid19">19</a>]. In contrast, cluster headache was identified in seven (0.4 percent) [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Sex distribution</span><span class="headingEndMark"> — </span>Retrospective surveys suggested a female predominance in paroxysmal hemicrania [<a href="#rid17">17,21,22</a>], but a later prospective study found that the female-to-male ratio is approximately 1 to 1 [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Age of onset</span><span class="headingEndMark"> — </span>Paroxysmal hemicrania may begin at any age, although onset usually occurs during adulthood. The mean age of onset ranges from 34 to 41 years [<a href="#rid17">17,22,23</a>]. The youngest age at onset was one year and the oldest was 81 years [<a href="#rid17">17,24</a>]. In one case series, episodic paroxysmal hemicrania began earlier (mean 27 years) than chronic paroxysmal hemicrania (mean 37 years) [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The clinical phenotype of paroxysmal hemicrania is highly characteristic [<a href="#rid17">17,21,22,25,26</a>]. Patients typically have unilateral, brief, severe attacks of pain associated with cranial autonomic features that recur several times per day.</p><p class="headingAnchor" id="H7"><span class="h2">Character and location of pain</span><span class="headingEndMark"> — </span>The pain of paroxysmal hemicrania is typically excruciating in severity and most often described with the terms sharp, stabbing, throbbing, shooting, burning, or boring [<a href="#rid23">23</a>].</p><p>The headache is strictly unilateral. It occurs without side shift in &gt;95 percent of patients [<a href="#rid23">23</a>].The pain is most often in the ophthalmic trigeminal distribution (V1), but it can be extratrigeminal. The maximum pain is usually centered on the orbital, retroorbital, temporal, and frontal regions. Less often, the pain involves the occipital region, maxillary region, neck, ear, and teeth [<a href="#rid23">23</a>]. The pain may occasionally radiate into the ipsilateral shoulder and arm [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H1430550314"><span class="h2">Associated symptoms</span><span class="headingEndMark"> — </span>Attacks of paroxysmal hemicrania typically occur in association with ipsilateral cranial autonomic features.</p><p class="bulletIndent1"><span class="glyph">●</span>Lacrimation, conjunctival injection, rhinorrhea, nasal congestion, ptosis, or facial flushing frequently accompany the headache [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eyelid edema, forehead or facial sweating, aural fullness, aural swelling, miosis, or mydriasis are less frequently reported [<a href="#rid23">23</a>].</p><p></p><p>Photophobia and nausea may accompany some attacks, though vomiting and phonophobia are rare [<a href="#rid17">17</a>]. In a retrospective study of patients with chronic paroxysmal hemicrania, at least one migrainous feature of photophobia, nausea, or vomiting during an attack was present in 27 of 31 patients (87 percent) [<a href="#rid22">22</a>]. In a prospective study, photophobia accompanying chronic paroxysmal hemicrania was unilateral and on the same side as the pain in four of six patients [<a href="#rid27">27</a>]. Similarly, photophobia was unilateral in approximately one-half of patients with other trigeminal autonomic cephalalgias. In contrast, photophobia associated with migraine was unilateral in less than 10 percent of cases.</p><p>Agitation and pacing are often present during attacks of paroxysmal hemicrania. A prospective study of 31 patients found that agitation or restlessness was present in 25 patients (80 percent) during episodes of pain, while eight subjects (25 percent) were aggressive, more often verbally than physically [<a href="#rid23">23</a>]. In an earlier retrospective study, approximately one-half of patients with paroxysmal hemicrania attacks assumed the pacing activity usually seen with cluster headaches, while the other half preferred to sit or lie still [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H3906002339"><span class="h2">Temporal features</span><span class="headingEndMark"> — </span>Paroxysmal hemicrania attacks are typically brief, lasting several minutes, but may recur several times each day.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of the individual attacks</strong> — The headache usually lasts 2 to 30 minutes but may go on for up to two hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a prospective study of 105 attacks, the mean duration was 13 minutes, with a range of 3 to 46 minutes [<a href="#rid25">25,28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another prospective study of 31 patients reported a mean duration of 17 minutes, with a range of 10 seconds to 4 hours [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two retrospective studies, consisting of 84 and 74 patients, reported mean attack durations of 21 minutes (range 2 to 120 minutes) and 26 minutes, respectively [<a href="#rid17">17,22</a>].</p><p></p><p class="bulletIndent1">The headache has an abrupt onset and cessation. Interictal discomfort or pain is present in up to one-third of patients [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency and periodicity of attacks</strong> — In paroxysmal hemicrania, the attacks tend to occur at a high frequency, with a range from 1 to 40 daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a prospective study of 31 patients, the mean attack frequency was 11 (range 2 to 50) in 24 hours [<a href="#rid29">29</a>]. An earlier prospective study of 105 paroxysmal hemicrania attacks in five patients reported a mean attack frequency of 14 (range 4 to 38) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In two retrospective studies consisting of 84 and 74 patients, the mean attack frequency was 11 (range 2 to 40) and 6 daily, respectively [<a href="#rid17">17,22</a>].</p><p></p><p class="bulletIndent1">The attacks occur regularly throughout the 24-hour period without a preponderance of nocturnal attacks as is seen in cluster headache. However, nocturnal attacks associated with the rapid eye movement (REM) phase of sleep have been described [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">Attacks frequently recur continuously or with brief remissions, but some patients may have episodic bouts with remissions lasting for months or years. (See <a class="local">'Chronic and episodic forms'</a> below.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Triggers</span><span class="headingEndMark"> — </span>Most attacks of paroxysmal hemicrania are spontaneous. However, a number of attack triggers have been reported. In a prospective report of 31 patients, the most common triggers of paroxysmal hemicrania attacks were stress or relaxation after stress in eight patients (26 percent), exercise in seven (23 percent), alcohol in six (19 percent), and neck movement in six (19 percent) [<a href="#rid23">23</a>]. Cutaneous triggering, such as touching the skin, chewing, or talking, is uncommon with paroxysmal hemicrania [<a href="#rid23">23</a>].</p><p>The relationship between menstruation and paroxysmal hemicrania attacks, if any, is undetermined. Oral contraceptive medications do not seem to influence the attack frequency. In some case series, paroxysmal hemicrania attacks improved or disappeared during pregnancy but reappeared after delivery [<a href="#rid31">31,32</a>]. There is no reported effect of menopause.</p><p class="headingAnchor" id="H12"><span class="h2">Atypical features</span><span class="headingEndMark"> — </span>There are case reports documenting unusual clinical features of paroxysmal hemicrania, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Side-alternating attacks [<a href="#rid33">33-36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral, short-lasting, frequent, indomethacin-responsive headaches without cranial autonomic features [<a href="#rid37">37-39</a>]. While these cases were reported as bilateral paroxysmal hemicrania, they may instead represent bilateral paroxysmal cephalalgia, a novel indomethacin-responsive primary headache syndrome [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral paroxysmal hemicrania with no autonomic features [<a href="#rid33">33,34,41</a>] and other cases of paroxysmal hemicrania with dissociation between pain and autonomic features [<a href="#rid36">36,42</a>]. Alternatively, it is possible that current criteria do not recognize the breadth of cranial autonomic features that may be associated with paroxysmal hemicrania. As an example, the sense of aural fullness reported by two patients [<a href="#rid41">41</a>] may be part of the spectrum of symptoms associated with cranial parasympathetic autonomic activation [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paroxysmal hemicrania manifested by ear pain and a sensation of external acoustic meatus obstruction and paroxysmal hemicrania associated with red ear syndrome [<a href="#rid41">41</a>]. The red ear syndrome is a rare condition characterized by otalgia and associated autonomic phenomena, including cutaneous erythema of the ear ipsilateral to the pain [<a href="#rid43">43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primarily extratrigeminal pain with paroxysmal hemicrania [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Typical migrainous aura occurring in association with paroxysmal hemicrania attacks [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Comorbidity</span><span class="headingEndMark"> — </span>Paroxysmal hemicrania has been observed in association with other headache disorders, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Trigeminal neuralgia [<a href="#rid47">47-52</a>] (see  <a class="medical medical_review" href="/d/html/5283.html" rel="external">"Trigeminal neuralgia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cluster headache [<a href="#rid13">13,53-55</a>] (see  <a class="medical medical_review" href="/d/html/3326.html" rel="external">"Cluster headache: Epidemiology, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Migraine [<a href="#rid22">22,56,57</a>] (see  <a class="medical medical_review" href="/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tension-type headache [<a href="#rid22">22</a>] (see  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary stabbing headache [<a href="#rid58">58</a>] (see  <a class="medical medical_review" href="/d/html/3327.html" rel="external">"Primary stabbing headache"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary cough headache [<a href="#rid59">59</a>] (see  <a class="medical medical_review" href="/d/html/3325.html" rel="external">"Primary cough headache"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemicrania continua [<a href="#rid60">60</a>] (see <a class="local">'Hemicrania continua'</a> below)</p><p></p><p>Typically, each type of headache must be treated for the patient to be headache free. Exceptions are primary stabbing headache and primary cough headache, which are also responsive to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>.</p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSIS AND EVALUATION</span><span class="headingEndMark"> — </span>The diagnosis of paroxysmal hemicrania is based upon a compatible clinical history in the setting of a normal neurologic examination. The diagnosis is confirmed by an optimum response to a therapeutic trial of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>. (See <a class="local">'Indomethacin trial'</a> below.)</p><p>In addition, we suggest performing a magnetic resonance imaging (MRI) of the brain with gadolinium contrast in all patients with paroxysmal hemicrania to exclude a structural brain lesion [<a href="#rid61">61</a>]. (See <a class="local">'Neuroimaging'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>For the diagnosis of paroxysmal hemicrania, the International Classification of Headache Disorders, 3<sup>rd</sup> edition (ICHD-3) requires fulfilling all of the following criteria  (<a class="graphic graphic_table graphicRef58505" href="/d/graphic/58505.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>At least 20 attacks</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe unilateral orbital, supra-orbital, and/or temporal pain lasting 2 to 30 minutes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Either or both of the following:</p><p></p><p class="bulletIndent2">(1) At least one of the following symptoms or signs, ipsilateral to the headache:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Conjunctival injection and/or lacrimation</p><p class="bulletIndent3"><span class="glyph">-</span>Nasal congestion and/or rhinorrhea</p><p class="bulletIndent3"><span class="glyph">-</span>Eyelid edema</p><p class="bulletIndent3"><span class="glyph">-</span>Forehead and facial sweating</p><p class="bulletIndent3"><span class="glyph">-</span>Miosis and/or ptosis</p><p></p><p class="bulletIndent2">(2) A sense of restlessness or agitation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Attacks have a frequency &gt;5 per day for more than half of the active time course</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevented absolutely by therapeutic doses of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not better accounted for by another ICHD-3 disorder</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Chronic and episodic forms</span><span class="headingEndMark"> — </span>Paroxysmal hemicrania is further classified depending on the presence of a remission period [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic paroxysmal hemicrania (CPH)</strong> – Persistent symptoms with no remission within one year or brief remissions that last less than three months. CPH represents approximately 80 percent of patients with paroxysmal hemicrania.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Episodic paroxysmal hemicrania (EPH)</strong> – Characterized by recurrent bouts, each with a duration of seven days to one year (when untreated), separated by pain-free remissions lasting three months or longer. EPH occurs in 20 percent of patients with paroxysmal hemicrania.</p><p></p><p>In EPH, the typical duration of the headache bout ranges from two weeks to four and a half months; remission periods range from 1 to 36 months [<a href="#rid21">21</a>]. EPH has been reported to stay episodic for up to 35 years [<a href="#rid17">17</a>]. EPH can evolve into typical CPH and vice versa. Notably in paroxysmal hemicrania, the chronic form dominates the clinical presentation. Approximately one-quarter of the CPH cases evolve from EPH, while the remaining three-quarters are chronic from onset [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Indomethacin trial</span><span class="headingEndMark"> — </span>We recommend a therapeutic trial of oral <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> for patients with active paroxysmal hemicrania who do not have a contraindication. In patients who do not respond to an optimum trial of indomethacin, the diagnosis of paroxysmal hemicrania should be reconsidered. Paroxysmal hemicrania responds in a dramatic and absolute fashion to indomethacin, thereby underlining the importance of distinguishing it from cluster headache and the syndrome of short-lasting unilateral neuralgiform headache attacks, both of which are not responsive to indomethacin [<a href="#rid62">62,63</a>]. (See  <a class="medical medical_review" href="/d/html/3338.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Treatment and prognosis"</a>.)</p><p>The existence of indomethacin-insensitive paroxysmal hemicrania is controversial, but some patients who have clinical symptoms consistent with paroxysmal hemicrania do not respond to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid22">22,64</a>].</p><p class="headingAnchor" id="H529526052"><span class="h3">Regimen</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical dosing</strong> – The starting dose of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> is 75 mg daily in three divided doses (ie, 25 mg three times a day). The indomethacin dose should be increased to 150 mg daily in three divided doses for 3 to 10 days if there is no response or a partial response to the starting dose after three days. The dose should be further increased to 225 mg daily in three divided doses for 10 days for partial responders if the index of suspicion is high.</p><p></p><p class="bulletIndent1">Complete resolution of the headache is usually prompt, occurring within one to two days of initiating the effective dose, though we have a patient who required 10 days to respond completely to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> (unpublished observation). It is therefore worth considering prolonging the administration of the maximum indomethacin dose to 10 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral dosing option </strong>– Where available, parenteral <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> given intramuscularly has been proposed as a diagnostic test (the "indotest") for paroxysmal hemicrania. Two open-label studies of intramuscular indomethacin (100 mg) in six and seven patients reported complete pain relief for a mean of 11.1±3.5 and 13.4±7.7 hours, respectively [<a href="#rid65">65,66</a>].</p><p></p><p class="bulletIndent1">The indotest has the advantage that the diagnosis can be rapidly established, although it needs further validation at this stage with placebo-controlled trials. Intramuscular <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> is not available in some countries, including the United States.</p><p></p><p class="headingAnchor" id="H19"><span class="h3">Utility of trial for other trigeminal autonomic cephalalgias</span><span class="headingEndMark"> — </span>It could be advocated that all patients diagnosed with trigeminal autonomic cephalalgias  (<a class="graphic graphic_table graphicRef65541" href="/d/graphic/65541.html" rel="external">table 2</a>) who do not have a contraindication to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) should have a trial of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> at the start of treatment to detect the indomethacin-sensitive group, at least until a reliable biologic marker becomes available. However, the diagnostic yield will be low, since paroxysmal hemicrania is rare. In addition, this approach will delay appropriate treatment by one to two weeks in patients with cluster headache, unless there is access to the indotest. (See <a class="local">'Indomethacin trial'</a> above.)</p><p>The alternative approach is to consider an <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> trial only in patients with a high likelihood of having paroxysmal hemicrania. We routinely perform a trial of indomethacin in patients with trigeminal autonomic cephalalgias having more than five attacks daily or attacks lasting less than 30 minutes or both. In addition, we consider such a trial in patients with chronic trigeminal autonomic cephalalgias (before committing them to potentially multiple trials of treatment if paroxysmal hemicrania is missed) and patients with cluster headache who are refractory to usual cluster headache treatments.</p><p class="headingAnchor" id="H1112634211"><span class="h3">Pathophysiologic rationale</span><span class="headingEndMark"> — </span>What is the basis of the robust effect of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> in paroxysmal hemicrania? Though various hypotheses have been proposed to account for the efficacy of indomethacin in certain primary headache syndromes, its mechanism and site of action remain unclear.</p><p>This engenders the question as to whether paroxysmal hemicrania (and hemicrania continua) always demonstrate a robust response to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> and, therefore, can be classified on the basis of this specific treatment response. Though the current classification criteria require an absolute response to indomethacin for diagnosis [<a href="#rid3">3</a>], this is problematic for several reasons [<a href="#rid63">63,67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The therapeutic response in patients with paroxysmal hemicrania or hemicrania continua is not exclusive to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>; a variety of other medications have been reported to be effective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A response to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> is not specific to paroxysmal hemicrania or hemicrania continua; other primary headache syndromes also demonstrate a robust, albeit less consistent, response to indomethacin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients have been described who had the clinical phenotype of paroxysmal hemicrania or hemicrania continua but did not respond to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>. This raises the possibility that there is a subset of patients with the underlying biology and clinical phenotype of these syndromes who do not respond to indomethacin. Alternatively, the indomethacin-resistant cases do not represent true paroxysmal hemicrania or hemicrania continua if the mode of action of indomethacin involves interrupting the central pathogenetic mechanism of these syndromes.</p><p></p><p>These considerations highlight the importance of understanding the mechanism of action of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> and the pathophysiologic basis of these disorders.</p><p>So what special feature of the pharmacology of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> accounts for its specific effect in these headache syndromes? Similar to other NSAIDs, indomethacin is a potent reversible inhibitor of prostaglandin-forming cyclooxygenase (COX). However, the mechanism of action of indomethacin in paroxysmal hemicrania and hemicrania continua seems to be independent of an effect on prostaglandin synthesis, since other NSAIDs or COX-2 inhibitors appear to have a poor, partial, or inconsistent effect in these disorders. Although indomethacin shows selectivity for COX-1 over COX-2 inhibition, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="9781" href="/d/drug information/9781.html" rel="external">piroxicam</a> are equally potent COX-1 inhibitors and yet do not have as robust a treatment effect on these disorders [<a href="#rid68">68</a>].</p><p>The description of plasma protein extravasation into the dura mater of the rat after stimulation of the trigeminal ganglion led to the suggestion that this form of neurogenic inflammation may be partly responsible for the maintenance of head pain in primary neurovascular syndromes [<a href="#rid69">69</a>]. Plasma protein extravasation can be blocked by <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> but also by <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, triptans, ergots, gamma-aminobutyric acid agonists, glucocorticoids, and substance P antagonists, thereby making it unlikely to be the mechanism of action of indomethacin in the indomethacin-responsive headache syndromes [<a href="#rid70">70-72</a>]. Moreover, the potent inhibition of plasma protein extravasation by triptans [<a href="#rid73">73</a>] contrasts with its rather indifferent effect in paroxysmal hemicrania and hemicrania continua.</p><p>The neuropeptide calcitonin gene-related peptide (CGRP) is expressed in the trigeminovascular system and is a marker of trigeminal nociception. It is released in primary headache syndromes such as migraine, cluster headache, and PH, and levels normalized following successful treatment with <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid74">74</a>].</p><p><a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">Indomethacin</a> has also been shown to inhibit the production of nitric oxide [<a href="#rid75">75</a>]. Nitric oxide plays a critical role in the neurogenic control of the cerebral circulation and has been implicated in the pathogenesis of primary neurovascular headaches, including the trigeminal autonomic cephalalgias [<a href="#rid76">76</a>]. While other NSAIDS inhibit neurogenic induced vasodilation, an in vivo study in mice found that only indomethacin was able to inhibit nitric oxide-induced vasodilation, thus distinguishing it from <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> and <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> [<a href="#rid77">77</a>]. As discussed separately, the pathophysiology of the trigeminal autonomic cephalalgias revolves around the trigeminal-autonomic reflex. (See  <a class="medical medical_review" href="/d/html/3339.html" rel="external">"Pathophysiology of the trigeminal autonomic cephalalgias"</a>.)</p><p>The facial (cranial nerve VII) cranial parasympathetic outflow ganglia, sphenopalatine, and otic ganglia contain nitric oxide synthase, and nitric oxide generation is involved in the vasodilator responses of this system [<a href="#rid78">78</a>]. Nitric oxide is colocalized with vasoactive intestinal peptide [<a href="#rid78">78,79</a>], a neuropeptide that is markedly increased during an attack of paroxysmal hemicrania and normalized after treatment with <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid74">74</a>]. Thus, indomethacin may antagonize one or more steps in the nitric oxide pathway and, in this way, exert its effect on disorders characterized by activation of the cranial parasympathetic system. However, if this is the mechanism and site of action of indomethacin, then it remains unclear why it is ineffective for cluster headache and for the syndrome of short-lasting unilateral neuralgiform headache attacks. Another possibility that demands further study is that indomethacin may also act by inhibiting central nitrergic mechanisms.</p><p>Several studies in animals, normal volunteers, and patients with traumatic brain edema have demonstrated that <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> lowers intracranial pressure, improves cerebral perfusion pressure, and causes a substantial dose-related reduction of the cerebral blood flow [<a href="#rid80">80-83</a>]. However, this mechanism of action of indomethacin is unlikely to be the mode of action in paroxysmal hemicrania and hemicrania continua; there is no pathophysiologic evidence that these headaches are caused by disordered intracranial pressure.</p><p class="headingAnchor" id="H20"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Since a relatively high number of secondary cases of paroxysmal hemicrania have been reported, we suggest a brain MRI with gadolinium for all patients with paroxysmal hemicrania to exclude a structural brain lesion, particularly one involving the pituitary fossa [<a href="#rid61">61</a>]. Even cases fitting all criteria for paroxysmal hemicrania, including a complete response to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, can have a potential secondary etiology.</p><p class="headingAnchor" id="H3841708804"><span class="h2">Additional testing for patients with atypical features</span><span class="headingEndMark"> — </span>Further investigations are required when features are atypical to evaluate for secondary paroxysmal hemicrania. These features include:</p><p class="bulletIndent1"><span class="glyph">●</span>Atypical character or pain or temporal features.</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal neurologic signs on examination.</p><p class="bulletIndent1"><span class="glyph">●</span>Response to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> is poor, or dose is escalating for symptom management.</p><p></p><p>In such cases, in addition to an appropriate initial neuroimaging study that adequately evaluates the pituitary fossa, we also recommend the following investigations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pituitary function tests</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete blood count</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasculitis laboratory screening</strong> (see  <a class="medical medical_review" href="/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lumbar puncture</strong> (including opening pressure to assess for intracranial hypertension, even in the face of response to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, particularly if the pain becomes bilateral)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiograph</strong> (eg, to assess for a Pancoast tumor)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of strictly unilateral, brief but frequent headaches is:</p><p class="bulletIndent1"><span class="glyph">●</span>Paroxysmal hemicrania (primary and secondary forms)</p><p class="bulletIndent1"><span class="glyph">●</span>Cluster headache</p><p class="bulletIndent1"><span class="glyph">●</span>The syndrome of short-lasting unilateral neuralgiform headache attacks</p><p class="bulletIndent1"><span class="glyph">●</span>Trigeminal neuralgia</p><p class="bulletIndent1"><span class="glyph">●</span>Primary stabbing headache</p><p></p><p>One-third of patients with paroxysmal hemicrania report interictal pain. In such cases, hemicrania continua should be considered in the differential diagnosis.</p><p class="headingAnchor" id="H22"><span class="h2">Secondary paroxysmal hemicrania</span><span class="headingEndMark"> — </span>Secondary (symptomatic) paroxysmal hemicrania is relatively common and can be associated with diverse pathologic processes at various sites, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following coil embolization of a supraclinoid carotid artery aneurysm [<a href="#rid84">84</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Cerebral arteriovenous malformation [<a href="#rid85">85</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Middle cerebral artery territory infarction [<a href="#rid85">85</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Occipital infarction [<a href="#rid86">86</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumors</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pituitary adenoma [<a href="#rid22">22,87,88</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Frontal lobe tumor [<a href="#rid89">89</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Gangliocytoma of the sella turcica [<a href="#rid90">90</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Cavernous sinus meningioma [<a href="#rid91">91</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Petrous ridge meningioma [<a href="#rid22">22</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Intracranial parotid carcinoma metastases [<a href="#rid92">92,93</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Pancoast tumor [<a href="#rid94">94</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Tuber cinereum hamartoma [<a href="#rid21">21</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Miscellaneous</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Collagen vascular disease [<a href="#rid89">89</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Essential thrombocythemia [<a href="#rid95">95</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Intracranial hypertension [<a href="#rid96">96</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Maxillary cyst [<a href="#rid87">87</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmic herpes zoster [<a href="#rid97">97</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Post-traumatic [<a href="#rid42">42</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Medication adverse effect (eg, phosphodiesterase inhibitors) [<a href="#rid98">98</a>]</p><p></p><p>Even cases fitting all criteria for paroxysmal hemicrania, including a complete response to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, can have a potential secondary etiology. Thus, we suggest neuroimaging for all patients with suspected paroxysmal hemicrania [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Cluster headache</span><span class="headingEndMark"> — </span>There is a considerable overlap in the clinical phenotype of paroxysmal hemicrania and cluster headache; both are strictly unilateral and relatively brief but frequent headaches that occur in association with ipsilateral cranial autonomic features. (See  <a class="medical medical_review" href="/d/html/3326.html" rel="external">"Cluster headache: Epidemiology, clinical features, and diagnosis"</a>.)</p><p>Paroxysmal hemicrania differs from cluster headache because of its female predominance, shorter duration of headaches, more frequent attacks, and the absolute response to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>. The episodic form of headache attacks are more common in cluster headache. In addition, circannual periodicity does not appear to be a feature of EPH, though three cases with seasonal onset have been described [<a href="#rid10">10,11,46</a>]. However, the utility of these features to distinguish paroxysmal hemicrania from cluster headache is limited by the considerable overlap of these characteristics in the two syndromes.</p><p>Mistaking paroxysmal hemicrania for cluster headache is problematic since generally treatments for cluster headache are not effective for paroxysmal hemicrania. The possible role of an <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> trial in the diagnosis of trigeminal autonomic cephalalgias is discussed above. (See <a class="local">'Utility of trial for other trigeminal autonomic cephalalgias'</a> above.)</p><p class="headingAnchor" id="H24"><span class="h2">Short-lasting unilateral neuralgiform headache attacks</span><span class="headingEndMark"> — </span>The syndrome of short-lasting unilateral neuralgiform headache attacks is divided into two subtypes: </p><p class="bulletIndent1"><span class="glyph">●</span>Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Short-lasting unilateral neuralgiform headache attacks with cranial autonomic features (SUNA)</p><p></p><p>These headaches differ from paroxysmal hemicrania with regard to attack duration, temporal distribution of attacks, attack triggers, sex preponderance, and response to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>  (<a class="graphic graphic_table graphicRef65541" href="/d/graphic/65541.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/3336.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Ophthalmic division trigeminal neuralgia</span><span class="headingEndMark"> — </span>Trigeminal neuralgia attacks involving the first division (ophthalmic or V1) of the trigeminal nerve generally last less than five seconds, with durations longer than 30 seconds being very rare [<a href="#rid99">99</a>]. The attacks are accompanied by sparse or no autonomic features [<a href="#rid29">29</a>]. Ophthalmic division trigeminal neuralgia attacks are typically precipitated by stimuli within the trigeminal-innervated distribution. Some patients with paroxysmal hemicrania exhibit precipitation mechanisms acting on the nuchal and cervical areas, but no trigeminal trigger zones have been described. Trigeminal neuralgia typically responds well to <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>. (See  <a class="medical medical_review" href="/d/html/5283.html" rel="external">"Trigeminal neuralgia"</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Primary stabbing headache</span><span class="headingEndMark"> — </span>Primary stabbing headache refers to brief, sharp, or jabbing pain in the head that occurs either as a single episode or in brief repeated volleys. The pain is usually over the ophthalmic trigeminal distribution, while the face is generally spared. The pain usually lasts a fraction of a second but can persist for up to one minute and recurs at irregular intervals (hours to days). The attacks commonly subside with the administration of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid100">100</a>]. (See  <a class="medical medical_review" href="/d/html/3327.html" rel="external">"Primary stabbing headache"</a>.)</p><p>These headaches are generally easily distinguishable clinically as they differ in several respects: in primary stabbing headache, the site and radiation of pain often varies between attacks, the attacks are very brief, and cranial autonomic features are absent.</p><p class="headingAnchor" id="H27"><span class="h2">Hemicrania continua</span><span class="headingEndMark"> — </span>Hemicrania continua is a strictly unilateral, continuous headache of mild to moderate intensity, with superimposed exacerbations of moderate to severe intensity that are accompanied by trigeminal autonomic features and migrainous symptoms. The syndrome is exquisitely responsive to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>. (See  <a class="medical medical_review" href="/d/html/3342.html" rel="external">"Hemicrania continua"</a>.)</p><p>Differentiating hemicrania continua and paroxysmal hemicrania, when the latter has interictal pain, can be particularly problematic. Some clinical features can help:</p><p class="bulletIndent1"><span class="glyph">●</span>Interictal pain in paroxysmal hemicrania is usually described as mild only, whereas background pain in hemicrania continua is often moderate (although it can be mild).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exacerbations in paroxysmal hemicrania are short-lasting, whereas those in hemicrania continua are longer, often lasting several hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The severity of pain during exacerbations is excruciating in paroxysmal hemicrania, whereas it is often moderate or severe in hemicrania continua.</p><p></p><p class="headingAnchor" id="H3231486640"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Paroxysmal hemicrania is an uncommon-type trigeminal autonomic cephalalgia  (<a class="graphic graphic_table graphicRef65541" href="/d/graphic/65541.html" rel="external">table 2</a>). Paroxysmal hemicrania may begin at any age, although onset usually occurs during adulthood. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with paroxysmal hemicrania characteristically have unilateral, brief, severe attacks of pain associated with cranial autonomic features that recur several times per day. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The headache is strictly unilateral, most often in the ophthalmic trigeminal distribution. The headache usually lasts 2 to 30 minutes but may persist for up to two hours. The mean attack frequency is 11 to 14 daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ipsilateral cranial autonomic features, such as lacrimation, conjunctival injection, nasal congestion, or rhinorrhea, frequently accompany the headache; eyelid edema, ptosis, miosis, and facial sweating are less frequent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The diagnosis of paroxysmal hemicrania is based upon a compatible clinical history in the setting of a normal neurologic examination  (<a class="graphic graphic_table graphicRef58505" href="/d/graphic/58505.html" rel="external">table 1</a>). The diagnosis is confirmed by an optimum therapeutic trial of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> once structural causes have been excluded with neuroimaging. (See <a class="local">'Diagnosis and evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">Indomethacin</a><strong> trial</strong> – For patients with active paroxysmal hemicrania who do not have contraindication, we recommend a therapeutic trial of oral indomethacin. Complete resolution of the headache is usually prompt, occurring within one to two days of initiating the effective dose. (See <a class="local">'Indomethacin trial'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuroimaging</strong> – For all patients with suspected paroxysmal hemicrania, we suggest magnetic resonance imaging of the brain with gadolinium to exclude a structural brain or pituitary lesion. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional testing for atypical cases</strong> – Laboratory and other diagnostic testing is generally reserved for patients with atypical symptoms, abnormal neurologic examination, or poor response to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>. These include (see <a class="local">'Additional testing for patients with atypical features'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pituitary function tests</p><p class="bulletIndent3"><span class="glyph">-</span>Complete blood count</p><p class="bulletIndent3"><span class="glyph">-</span>Vasculitis laboratory screen</p><p class="bulletIndent3"><span class="glyph">-</span>Lumbar puncture</p><p class="bulletIndent3"><span class="glyph">-</span>Chest radiograph</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of strictly unilateral, brief but frequent headaches is (see <a class="local">'Differential diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary and secondary forms of paroxysmal hemicrania</p><p class="bulletIndent2"><span class="glyph">•</span>Cluster headache</p><p class="bulletIndent2"><span class="glyph">•</span>The syndrome of short-lasting unilateral neuralgiform headache attacks</p><p class="bulletIndent2"><span class="glyph">•</span>Trigeminal neuralgia</p><p class="bulletIndent2"><span class="glyph">•</span>Primary stabbing headache</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.</a></li><li><a class="nounderline abstract_t">Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161:692.</a></li><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Dale I. Evidence for a new (?), treatable headache entity. Headache 1974; 14:105.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Dale I. A new (?) Clinical headache entity "chronic paroxysmal hemicrania" 2. Acta Neurol Scand 1976; 54:140.</a></li><li><a class="nounderline abstract_t">Kudrow L, Esperanca P, Vijayan N. Episodic paroxysmal hemicrania? Cephalalgia 1987; 7:197.</a></li><li><a class="nounderline abstract_t">Blau JN, Engel H. Episodic paroxysmal hemicrania: a further case and review of the literature. J Neurol Neurosurg Psychiatry 1990; 53:343.</a></li><li><a class="nounderline abstract_t">Coria F, Claveria LE, Jimenez-Jimenez FJ, de Seijas EV. Episodic paroxysmal hemicrania responsive to calcium channel blockers. J Neurol Neurosurg Psychiatry 1992; 55:166.</a></li><li><a class="nounderline abstract_t">Newman LC, Gordon ML, Lipton RB, et al. Episodic paroxysmal hemicrania: two new cases and a literature review. Neurology 1992; 42:964.</a></li><li><a class="nounderline abstract_t">Veloso GG, Kaup AO, Peres MF, Zukerman E. Episodic paroxysmal hemicrania with seasonal variation: case report and the EPH-cluster headache continuum hypothesis. Arq Neuropsiquiatr 2001; 59:944.</a></li><li><a class="nounderline abstract_t">Siow HC. Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors. Cephalalgia 2004; 24:414.</a></li><li><a class="nounderline abstract_t">Rapoport AM, Sheftell FD, Baskin SM. Chronic paroxysmal hemicrania--case report of the second known definite occurrence in a male. Cephalalgia 1981; 1:67.</a></li><li><a class="nounderline abstract_t">Tehindrazanarivelo AD, Visy JM, Bousser MG. Ipsilateral cluster headache and chronic paroxysmal hemicrania: two case reports. Cephalalgia 1992; 12:318.</a></li><li><a class="nounderline abstract_t">Zidverc-Trajkovic J, Pavlovic AM, Mijajlovic M, et al. Cluster headache and paroxysmal hemicrania: differential diagnosis. Cephalalgia 2005; 25:244.</a></li><li><a class="nounderline abstract_t">Joubert J, Powell D, Djikowski J. Chronic paroxysmal hemicrania in a South African black. A case report. Cephalalgia 1987; 7:193.</a></li><li><a class="nounderline abstract_t">Chakravarty A, Mukherjee A, Roy D. Trigeminal autonomic cephalgias and variants: clinical profile in Indian patients. Cephalalgia 2004; 24:859.</a></li><li><a class="nounderline abstract_t">Antonaci F, Sjaastad O. Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. Headache 1989; 29:648.</a></li><li><a class="nounderline abstract_t">Russell MB. Epidemiology and genetics of cluster headache. Lancet Neurol 2004; 3:279.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Bakketeig LS. The rare, unilateral headaches. Vågå study of headache epidemiology. J Headache Pain 2007; 8:19.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Bakketeig LS. Cluster headache prevalence. Vågå study of headache epidemiology. Cephalalgia 2003; 23:528.</a></li><li><a class="nounderline abstract_t">Pauri F, Tilia G, Cisternino M. Tuber cinereum hamartomas mimicking chronic paroxysmal hemicrania. Ital J Neurol Sci 1993; 14 Suppl 7:132.</a></li><li><a class="nounderline abstract_t">Boes CJ, Dodick DW. Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients. Headache 2002; 42:699.</a></li><li><a class="nounderline abstract_t">Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: a prospective clinical study of 31 cases. Brain 2008; 131:1142.</a></li><li><a class="nounderline abstract_t">de Almeida DB, Cunali PA, Santos HL, et al. Chronic paroxysmal hemicrania in early childhood: case report. Cephalalgia 2004; 24:608.</a></li><li class="breakAll">Russell D. Paroxysmal hemicrania. In: Cluster Headache &amp; Related Conditions, Olesen J, Goadsby PJ (Eds), Oxford University Press, Oxford 1999. p.27.</li><li><a class="nounderline abstract_t">Blankenburg M, Hechler T, Dubbel G, et al. Paroxysmal hemicrania in children--symptoms, diagnostic criteria, therapy and outcome. Cephalalgia 2009; 29:873.</a></li><li><a class="nounderline abstract_t">Irimia P, Cittadini E, Paemeleire K, et al. Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias. Cephalalgia 2008; 28:626.</a></li><li><a class="nounderline abstract_t">Russell D. Chronic paroxysmal hemicrania: severity, duration and time of occurrence of attacks. Cephalalgia 1984; 4:53.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Matharu MS, Boes CJ. SUNCT syndrome or trigeminal neuralgia with lacrimation. Cephalalgia 2001; 21:82.</a></li><li><a class="nounderline abstract_t">Kayed K, Godtlibsen OB, Sjaastad O. Chronic paroxysmal hemicrania IV: "REM sleep locked" nocturnal headache attacks. Sleep 1978; 1:91.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Apfelbaum R, Caskey W, et al. Chronic paroxysmal hemicrania (CPH). The clinical manifestations. A review. Ups J Med Sci Suppl 1980; 31:27.</a></li><li><a class="nounderline abstract_t">Stein HJ, Rogado AZ. Headache rounds. Chronic paroxysmal hemicrania: two new patients. Headache 1980; 20:72.</a></li><li><a class="nounderline abstract_t">Pelz M, Merskey H. A case of pre-chronic paroxysmal hemicrania. Cephalalgia 1982; 2:47.</a></li><li><a class="nounderline abstract_t">Bogucki A, Szymańska R, Braciak W. Chronic paroxysmal hemicrania: lack of pre-chronic stage. Cephalalgia 1984; 4:187.</a></li><li><a class="nounderline abstract_t">Pradalier A, Dry J. [Chronic paroxysmal hemicrania. Treatment with indomethacin and diclofenac]. Therapie 1984; 39:185.</a></li><li><a class="nounderline abstract_t">Pareja JA. Chronic paroxysmal hemicrania: dissociation of the pain and autonomic features. Headache 1995; 35:111.</a></li><li><a class="nounderline abstract_t">Pöllmann W, Pfaffenrath V. Chronic paroxysmal hemicrania: the first possible bilateral case. Cephalalgia 1986; 6:55.</a></li><li><a class="nounderline abstract_t">Mulder LJ, Spierings EL. Non-lateralized pain in a case of chronic paroxysmal hemicrania? Cephalalgia 2004; 24:52.</a></li><li><a class="nounderline abstract_t">Bingel U, Weiller C. An unusual indomethacin-sensitive headache: a case of bilateral episodic paroxysmal hemicrania without autonomic symptoms? Cephalalgia 2005; 25:148.</a></li><li><a class="nounderline abstract_t">Matharu MS, Goadsby PJ. Bilateral paroxysmal hemicrania or bilateral paroxysmal cephalalgia, another novel indomethacin-responsive primary headache syndrome? Cephalalgia 2005; 25:79.</a></li><li><a class="nounderline abstract_t">Boes CJ, Swanson JW, Dodick DW. Chronic paroxysmal hemicrania presenting as otalgia with a sensation of external acoustic meatus obstruction: two cases and a pathophysiologic hypothesis. Headache 1998; 38:787.</a></li><li><a class="nounderline abstract_t">Matharu MJ, Goadsby PJ. Post-traumatic chronic paroxysmal hemicrania (CPH) with aura. Neurology 2001; 56:273.</a></li><li><a class="nounderline abstract_t">Purdy RA, Dodick DW. Red ear syndrome. Curr Pain Headache Rep 2007; 11:313.</a></li><li><a class="nounderline abstract_t">Ryan S, Wakerley BR, Davies P. Red ear syndrome: a review of all published cases (1996-2010). Cephalalgia 2013; 33:190.</a></li><li><a class="nounderline abstract_t">Dodick DW. Extratrigeminal episodic paroxysmal hemicrania. Further clinical evidence of functionally relevant brain stem connections. Headache 1998; 38:794.</a></li><li><a class="nounderline abstract_t">Rossi P, Di Lorenzo G, Faroni J, Sauli E. Seasonal, extratrigeminal, episodic paroxysmal hemicrania successfully treated with single suboccipital steroid injections. Eur J Neurol 2005; 12:903.</a></li><li><a class="nounderline abstract_t">Hannerz J. Trigeminal neuralgia with chronic paroxysmal hemicrania: the CPH-tic syndrome. Cephalalgia 1993; 13:361.</a></li><li><a class="nounderline abstract_t">Caminero AB, Pareja JA, Dobato JL. Chronic paroxysmal hemicrania-tic syndrome. Cephalalgia 1998; 18:159.</a></li><li><a class="nounderline abstract_t">Zukerman E, Peres MF, Kaup AO, et al. Chronic paroxysmal hemicrania-tic syndrome. Neurology 2000; 54:1524.</a></li><li><a class="nounderline abstract_t">Martínez-Salio A, Porta-Etessam J, Pérez-Martínez D, et al. Case reports: chronic paroxysmal hemicrania-tic syndrome. Headache 2000; 40:682.</a></li><li><a class="nounderline abstract_t">Boes CJ, Matharu MS, Goadsby PJ. The paroxysmal hemicrania-tic syndrome. Cephalalgia 2003; 23:24.</a></li><li><a class="nounderline abstract_t">Sanahuja J, Vazquez P, Falguera M. Paroxysmal hemicrania-tic syndrome responsive to acetazolamide. Cephalalgia 2005; 25:547.</a></li><li><a class="nounderline abstract_t">Jotkowitz S. Chronic paroxysmal hemicrania and cluster. Ann Neurol 1978; 4:389.</a></li><li><a class="nounderline abstract_t">Pearce SH, Cox JG, Pearce JM. Chronic paroxysmal hemicrania, episodic cluster headache and classic migraine in one patient. J Neurol Neurosurg Psychiatry 1987; 50:1699.</a></li><li><a class="nounderline abstract_t">Centonze V, Bassi A, Causarano V, et al. Simultaneous occurrence of ipsilateral cluster headache and chronic paroxysmal hemicrania: a case report. Headache 2000; 40:54.</a></li><li><a class="nounderline abstract_t">Cohen AS, Matharu MS, Goadsby PJ. Paroxysmal hemicrania in a family. Cephalalgia 2006; 26:486.</a></li><li><a class="nounderline abstract_t">Pareja J, Pareja J. Chronic paroxysmal hemicrania coexisting with migraine. Differential response to pharmacological treatment. Headache 1992; 32:77.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Egge K, Hørven I, et al. Chronic paroxysmal hemicranial: mechanical precipitation of attacks. Headache 1979; 19:31.</a></li><li><a class="nounderline abstract_t">Mateo I, Pascual J. Coexistence of chronic paroxysmal hemicrania and benign cough headache. Headache 1999; 39:437.</a></li><li><a class="nounderline abstract_t">Müller KI, Bekkelund SI. Hemicrania continua changed to chronic paroxysmal hemicrania after treatment with cyclooxygenase-2 inhibitor. Headache 2011; 51:300.</a></li><li><a class="nounderline abstract_t">Favier I, van Vliet JA, Roon KI, et al. Trigeminal autonomic cephalgias due to structural lesions: a review of 31 cases. Arch Neurol 2007; 64:25.</a></li><li><a class="nounderline abstract_t">Antonaci F, Costa A, Ghirmai S, et al. Parenteral indomethacin (the INDOTEST) in cluster headache. Cephalalgia 2003; 23:193.</a></li><li><a class="nounderline abstract_t">Matharu MS, Goadsby PJ. Functional brain imaging in hemicrania continua: implications for nosology and pathophysiology. Curr Pain Headache Rep 2005; 9:281.</a></li><li><a class="nounderline abstract_t">Fuad F, Jones NS. Paroxysmal hemicrania and cluster headache: two discrete entities or is there an overlap? Clin Otolaryngol Allied Sci 2002; 27:472.</a></li><li><a class="nounderline abstract_t">Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the 'indotest'. Headache 1998; 38:122.</a></li><li><a class="nounderline abstract_t">Matharu MS, Cohen AS, Frackowiak RS, Goadsby PJ. Posterior hypothalamic activation in paroxysmal hemicrania. Ann Neurol 2006; 59:535.</a></li><li><a class="nounderline abstract_t">Dodick D. Hemicrania continua: diagnostic criteria and nosologic status. Cephalalgia 2001; 21:869.</a></li><li><a class="nounderline abstract_t">Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997; 18:30.</a></li><li><a class="nounderline abstract_t">Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 1987; 7:4129.</a></li><li><a class="nounderline abstract_t">Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165:251.</a></li><li><a class="nounderline abstract_t">Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001; 53:167.</a></li><li class="breakAll">Cutrer FM, Limmroth V, Waeber C, et al. New targets for antimigraine drug development. In: Headache, Goadsby PJ, Silberstein SD (Eds), Butterworth-Heinemann, Philadelphia 1997. p.59.</li><li><a class="nounderline abstract_t">Moskowitz MA, Cutrer FM. SUMATRIPTAN: a receptor-targeted treatment for migraine. Annu Rev Med 1993; 44:145.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Edvinsson L. Neuropeptide changes in a case of chronic paroxysmal hemicrania--evidence for trigemino-parasympathetic activation. Cephalalgia 1996; 16:448.</a></li><li><a class="nounderline abstract_t">Du ZY, Li XY. Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitro. Int J Immunopharmacol 1999; 21:219.</a></li><li><a class="nounderline abstract_t">Thomsen LL, Olesen J. Nitric oxide in primary headaches. Curr Opin Neurol 2001; 14:315.</a></li><li><a class="nounderline abstract_t">Summ O, Andreou AP, Akerman S, Goadsby PJ. A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. J Headache Pain 2010; 11:477.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Uddman R, Edvinsson L. Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves. Brain Res 1996; 707:110.</a></li><li><a class="nounderline abstract_t">Uddman R, Goadsby PJ, Jansen-Olesen I, Edvinsson L. Helospectin-like peptides: immunochemical localization and effects on isolated cerebral arteries and on local cerebral blood flow in the cat. J Cereb Blood Flow Metab 1999; 19:61.</a></li><li><a class="nounderline abstract_t">Slavik RS, Rhoney DH. Indomethacin: a review of its cerebral blood flow effects and potential use for controlling intracranial pressure in traumatic brain injury patients. Neurol Res 1999; 21:491.</a></li><li><a class="nounderline abstract_t">Jensen K, Freundlich M, Bünemann L, et al. The effect of indomethacin upon cerebral blood flow in healthy volunteers. The influence of moderate hypoxia and hypercapnia. Acta Neurochir (Wien) 1993; 124:114.</a></li><li><a class="nounderline abstract_t">Biestro AA, Alberti RA, Soca AE, et al. Use of indomethacin in brain-injured patients with cerebral perfusion pressure impairment: preliminary report. J Neurosurg 1995; 83:627.</a></li><li><a class="nounderline abstract_t">Jensen K, Ohrström J, Cold GE, Astrup J. The effects of indomethacin on intracranial pressure, cerebral blood flow and cerebral metabolism in patients with severe head injury and intracranial hypertension. Acta Neurochir (Wien) 1991; 108:116.</a></li><li><a class="nounderline abstract_t">Irimia P, Barbosa C, Martinez-Vila E. Paroxysmal hemicrania after carotid aneurysm embolization. Cephalalgia 2005; 25:1096.</a></li><li><a class="nounderline abstract_t">Newman LC, Herskovitz S, Lipton RB, Solomon S. Chronic paroxysmal headache: two cases with cerebrovascular disease. Headache 1992; 32:75.</a></li><li><a class="nounderline abstract_t">Broeske D, Lenn NJ, Cantos E. Chronic paroxysmal hemicrania in a young child: possible relation to ipsilateral occipital infarction. J Child Neurol 1993; 8:235.</a></li><li><a class="nounderline abstract_t">Gatzonis S, Mitsikostas DD, Ilias A, et al. Two more secondary headaches mimicking chronic paroxysmal hemicrania. Is this the exception or the rule? Headache 1996; 36:511.</a></li><li><a class="nounderline abstract_t">Sarov M, Valade D, Jublanc C, Ducros A. Chronic paroxysmal hemicrania in a patient with a macroprolactinoma. Cephalalgia 2006; 26:738.</a></li><li><a class="nounderline abstract_t">Medina JL. Organic headaches mimicking chronic paroxysmal hemicrania. Headache 1992; 32:73.</a></li><li><a class="nounderline abstract_t">Vijayan N. Symptomatic chronic paroxysmal hemicrania. Cephalalgia 1992; 12:111.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Stovner LJ, Stolt-Nielsen A, et al. CPH and hemicrania continua: requirements of high indomethacin dosages--an ominous sign? Headache 1995; 35:363.</a></li><li><a class="nounderline abstract_t">Mariano da Silva H, Benevides-Luz I, Santos AC, et al. Chronic paroxysmal hemicrania as a manifestation of intracranial parotid gland carcinoma metastasis--a case report. Cephalalgia 2004; 24:223.</a></li><li><a class="nounderline abstract_t">Mariano HS, Bigal ME, Bordini CA, Speciali JG. Chronic paroxysmal hemicrania (CPH)-like syndrome as a first manifestation of cerebral metastasis of parotid epidermoid carcinoma: a case report [abstract]. Cephalalgia 1999; 19:442.</a></li><li><a class="nounderline abstract_t">Delreux V, Kevers L, Callewaert A. [Paroxysmal hemicrania preceding Pancoast's syndrome]. Rev Neurol (Paris) 1989; 145:151.</a></li><li><a class="nounderline abstract_t">MacMillan JC, Nukada H. Chronic paroxysmal hemicrania. N Z Med J 1989; 102:251.</a></li><li><a class="nounderline abstract_t">Hannerz J, Jogestrand T. Intracranial hypertension and sumatriptan efficacy in a case of chronic paroxysmal hemicrania which became bilateral. (The mechanism of indomethacin in CPH). Headache 1993; 33:320.</a></li><li><a class="nounderline abstract_t">Giacovazzo M, Di Sabato F, Gallo MF, et al. ["Chronic paroxysmal hemicrania" following ophthalmic herpes zoster]. Riv Eur Sci Med Farmacol 1992; 14:45.</a></li><li><a class="nounderline abstract_t">Taga A, Russo M, Genovese A, et al. Paroxysmal Hemicrania-Like Headache Secondary to Phosphodiesterase Inhibitors Administration: A Case Report. Headache 2017; 57:663.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Pareja JA, Zukerman E, et al. Trigeminal neuralgia. Clinical manifestations of first division involvement. Headache 1997; 37:346.</a></li><li><a class="nounderline abstract_t">Pareja JA, Kruszewski P, Caminero AB. SUNCT syndrome versus idiopathic stabbing headache (jabs and jolts syndrome). Cephalalgia 1999; 19 Suppl 25:46.</a></li></ol></div><div id="topicVersionRevision">Topic 3334 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9055807" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16141962" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trigeminal autonomic cephalalgias. Pathophysiology and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4851935" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evidence for a new (?), treatable headache entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/782140" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A new (?) Clinical headache entity "chronic paroxysmal hemicrania" 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3652203" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Episodic paroxysmal hemicrania?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2187950" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Episodic paroxysmal hemicrania: a further case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538227" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Episodic paroxysmal hemicrania responsive to calcium channel blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1579250" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Episodic paroxysmal hemicrania: two new cases and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11733843" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Episodic paroxysmal hemicrania with seasonal variation: case report and the EPH-cluster headache continuum hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15096232" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7346175" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chronic paroxysmal hemicrania--case report of the second known definite occurrence in a male.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1423564" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ipsilateral cluster headache and chronic paroxysmal hemicrania: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15773821" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cluster headache and paroxysmal hemicrania: differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3652202" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chronic paroxysmal hemicrania in a South African black. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15377317" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Trigeminal autonomic cephalgias and variants: clinical profile in Indian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2693408" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15099542" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Epidemiology and genetics of cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17221345" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The rare, unilateral headaches. Vågåstudy of headache epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12950378" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cluster headache prevalence. Vågåstudy of headache epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tuber cinereum hamartomas mimicking chronic paroxysmal hemicrania</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390632" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18252775" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Paroxysmal hemicrania: a prospective clinical study of 31 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15196305" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chronic paroxysmal hemicrania in early childhood: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15196305" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chronic paroxysmal hemicrania in early childhood: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19236385" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Paroxysmal hemicrania in children--symptoms, diagnostic criteria, therapy and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422722" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6538816" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Chronic paroxysmal hemicrania: severity, duration and time of occurrence of attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422087" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : SUNCT syndrome or trigeminal neuralgia with lacrimation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/227025" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chronic paroxysmal hemicrania IV: "REM sleep locked" nocturnal headache attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6935856" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chronic paroxysmal hemicrania (CPH). The clinical manifestations. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7372474" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Headache rounds. Chronic paroxysmal hemicrania: two new patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7116441" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A case of pre-chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6498933" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Chronic paroxysmal hemicrania: lack of pre-chronic stage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6729768" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [Chronic paroxysmal hemicrania. Treatment with indomethacin and diclofenac].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7737862" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Chronic paroxysmal hemicrania: dissociation of the pain and autonomic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3698094" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chronic paroxysmal hemicrania: the first possible bilateral case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687013" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Non-lateralized pain in a case of chronic paroxysmal hemicrania?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15658952" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : An unusual indomethacin-sensitive headache: a case of bilateral episodic paroxysmal hemicrania without autonomic symptoms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15658943" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bilateral paroxysmal hemicrania or bilateral paroxysmal cephalalgia, another novel indomethacin-responsive primary headache syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279905" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Chronic paroxysmal hemicrania presenting as otalgia with a sensation of external acoustic meatus obstruction: two cases and a pathophysiologic hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11160973" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Post-traumatic chronic paroxysmal hemicrania (CPH) with aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686397" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Red ear syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23207115" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Red ear syndrome: a review of all published cases (1996-2010).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279907" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Extratrigeminal episodic paroxysmal hemicrania. Further clinical evidence of functionally relevant brain stem connections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16241981" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Seasonal, extratrigeminal, episodic paroxysmal hemicrania successfully treated with single suboccipital steroid injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8242731" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Trigeminal neuralgia with chronic paroxysmal hemicrania: the CPH-tic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9595211" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chronic paroxysmal hemicrania-tic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10751271" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic paroxysmal hemicrania-tic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971666" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Case reports: chronic paroxysmal hemicrania-tic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12534576" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The paroxysmal hemicrania-tic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955044" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Paroxysmal hemicrania-tic syndrome responsive to acetazolamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/727748" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chronic paroxysmal hemicrania and cluster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3437308" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chronic paroxysmal hemicrania, episodic cluster headache and classic migraine in one patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10759906" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Simultaneous occurrence of ipsilateral cluster headache and chronic paroxysmal hemicrania: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16556252" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Paroxysmal hemicrania in a family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1551791" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Chronic paroxysmal hemicrania coexisting with migraine. Differential response to pharmacological treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/759403" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Chronic paroxysmal hemicranial: mechanical precipitation of attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279922" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Coexistence of chronic paroxysmal hemicrania and benign cough headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21284612" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hemicrania continua changed to chronic paroxysmal hemicrania after treatment with cyclooxygenase-2 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210806" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Trigeminal autonomic cephalgias due to structural lesions: a review of 31 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12662186" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Parenteral indomethacin (the INDOTEST) in cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16004846" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Functional brain imaging in hemicrania continua: implications for nosology and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472514" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Paroxysmal hemicrania and cluster headache: two discrete entities or is there an overlap?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9529768" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the 'indotest'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16489610" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Posterior hypothalamic activation in paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11903278" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hemicrania continua: diagnostic criteria and nosologic status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114728" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3694267" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2776831" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11301492" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Neurogenic inflammation in the context of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11301492" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Neurogenic inflammation in the context of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8386498" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : SUMATRIPTAN: a receptor-targeted treatment for migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8902256" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Neuropeptide changes in a case of chronic paroxysmal hemicrania--evidence for trigemino-parasympathetic activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348371" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11371754" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Nitric oxide in primary headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978816" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8866719" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9886356" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Helospectin-like peptides: immunochemical localization and effects on isolated cerebral arteries and on local cerebral blood flow in the cat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10439431" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Indomethacin: a review of its cerebral blood flow effects and potential use for controlling intracranial pressure in traumatic brain injury patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8304056" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The effect of indomethacin upon cerebral blood flow in healthy volunteers. The influence of moderate hypoxia and hypercapnia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7674011" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Use of indomethacin in brain-injured patients with cerebral perfusion pressure impairment: preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2031471" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The effects of indomethacin on intracranial pressure, cerebral blood flow and cerebral metabolism in patients with severe head injury and intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16232164" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Paroxysmal hemicrania after carotid aneurysm embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1551790" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Chronic paroxysmal headache: two cases with cerebrovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8409264" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Chronic paroxysmal hemicrania in a young child: possible relation to ipsilateral occipital infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8824008" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Two more secondary headaches mimicking chronic paroxysmal hemicrania. Is this the exception or the rule?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686914" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Chronic paroxysmal hemicrania in a patient with a macroprolactinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1551789" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Organic headaches mimicking chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1290485" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Symptomatic chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635724" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : CPH and hemicrania continua: requirements of high indomethacin dosages--an ominous sign?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009016" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Chronic paroxysmal hemicrania as a manifestation of intracranial parotid gland carcinoma metastasis--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Chronic paroxysmal hemicrania (CPH)-like syndrome as a first manifestation of cerebral metastasis of parotid epidermoid carcinoma: a case report [abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2727538" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : [Paroxysmal hemicrania preceding Pancoast's syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2726045" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8394301" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Intracranial hypertension and sumatriptan efficacy in a case of chronic paroxysmal hemicrania which became bilateral. (The mechanism of indomethacin in CPH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1529145" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : ["Chronic paroxysmal hemicrania" following ophthalmic herpes zoster].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28188618" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Paroxysmal Hemicrania-Like Headache Secondary to Phosphodiesterase Inhibitors Administration: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237408" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Trigeminal neuralgia. Clinical manifestations of first division involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10668121" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : SUNCT syndrome versus idiopathic stabbing headache (jabs and jolts syndrome).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
